

REMARKS

Reconsideration of the application is requested in view of the amendment to the Specification and the Remarks presented herein.

The claims in the application are claims 2 to 6, all other claims having been cancelled.

Applicants are presenting a new abstract herewith. The application has been reviewed and it is believed that all trademarks have been properly indicated with TM or ®. The specification has been amended to indicate the application is a continuation-in-part of application Serial No. 10/470,112 and filed herewith is a new declaration to refer thereto and PTO form 2038 for \$1,370 for unintentional delayed claim for priority.

Claims 2 to 6 were rejected under 35 USC 112, 2nd paragraph as being indefinite in not indicating how the 90 kD molecular weight was determined. Applicants point out that the molecular weight determination was made under the standard denaturing and reducing conditions.


Claims 2 to 6 were rejected under 35 USC 112, first paragraph as being unsupported for treating cancer broadly although it may be supported for treating lung and breast cancer.

Applicants respectfully traverse this ground of rejection since the claims are directed to treating cancers dependent growth factor GHRH and not cancers broadly. Applicants are submitting herewith 5 references relating to treatment of cancers of this type, namely small cell lung cancer (Kiaris, et al.), Caki-I renal adenocarcinoma (Jungwirth, et al.), human Osteosarcomas (Pinski, et al.), pancreatic cancers (Szepeshazi, et al.) and prostate carcinoma (Lamharzi, et al.). Therefore, it is deemed that one skilled in the art know what type of cancers are dependent on growth factor GHRH and how to treat the same so as to be enabling to such a person. Therefore, withdrawal of this ground of rejection is requested.

Moreover, Applicants are submitting herewith a graph to support the heterocarpine antitumoral activity showing the in vivo inhibition of the tumoral growth of NCI-H510 cells (cells of small cell cancer) treated with hetero carpine (curve in blue). The other curves correspond to the growth of cells untreated with heterocarpine (black curve with circles) or in the presence of a saline solution (gray curve with squares). Therefore, it is deemed that the utility has been demonstrated.

In view of the amendment to the specification and the above remarks, it is believed that the claims point out Applicants' patentable contribution and favorable reconsideration of the application is requested.

Respectfully submitted,
Hedman and Costigan


Charles A. Muserlian #19,683
Attorney for Applicants
Tel. 212 302 8989

CAM:mlp
Enclosures